ArticleBMC cancer2025

A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors.

Jian Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.